Glaucoma Management in Burbank & Greater Los Angeles

Most eye problems get your attention. A cataract dims and yellows the world. Dry eye stings. A torn retina throws sparks and floaters across your sight. Glaucoma does none of that. In its common forms it brings no pain, no redness, and no early change you would ever catch on your own — peripheral vision narrows so gradually that the brain quietly fills in the missing edges for years.

By the time something feels wrong, the disease is usually well along. That is the hard fact this page is built around, and it shapes everything below. An estimated 80 million people worldwide are living with glaucoma, a number projected to climb past 111 million by 2040; in the United States, the count is more than four million. The old nickname was earned honestly. The "silent thief of sight" steals before you know anything is gone.

One note on what this page covers. Glaucoma care runs on two tracks: daily medical management, and, when that is not enough, laser and surgery. This page is the first track: detection, monitoring, and eye-drop therapy. The procedures have a page of their own, our glaucoma laser and surgery options, because they deserve a full explanation rather than a paragraph. Most people with glaucoma are held steady on the medical track for years.

What glaucoma actually is: pressure and the nerve

Glaucoma is not one disease but a family of them, joined by a common ending: progressive damage to the optic nerve, the cable of roughly 1.0 to 1.2 million nerve fibers that carries everything your eye sees to your brain. Damage those fibers and the signal stops getting through. Lose enough of them and the vision they served is gone for good, because optic nerve fibers do not grow back.

The usual driver of that damage is pressure inside the eye. The mechanism, kept plain: your eye constantly produces a clear fluid called aqueous humor that feeds its front structures and keeps it firm. For pressure to hold steady, that fluid has to drain out as fast as it is made. It leaves through a sieve-like filter, the trabecular meshwork, set into the drainage angle where the iris meets the cornea, and from there into a circular vessel called Schlemm's canal that returns it to the bloodstream.

When that drainage system underperforms, fluid backs up and intraocular pressure (IOP) rises. Sustained high pressure bears on the optic nerve and, over months and years, wears its fibers down. In the most common type, primary open-angle glaucoma, the drainage angle looks open and normal. The meshwork is simply not filtering well, which is part of why nothing feels wrong while the damage adds up.

There is one caveat that changes how we screen. Pressure is the leading risk factor, not the entire story. Some people sustain optic nerve damage at pressures that sit inside the so-called normal range, a pattern called normal-tension glaucoma, which is why a single reassuring pressure reading is not a clean bill of health. The nerve has to be looked at directly.

Who carries more risk

Glaucoma can affect anyone, but the odds are not spread evenly, and knowing where you fall helps decide how closely you should be watched. Several factors push risk higher:

• Age. Risk rises steadily after 40, and more sharply after 60.
• Family history. A parent or sibling with glaucoma raises your own risk meaningfully. It is one of the strongest signals there is.
• Ancestry. Risk and severity vary by background. Glaucoma-related blindness is considerably more common among African Americans than among white Americans, often with earlier onset, and people of Hispanic and Asian heritage carry elevated risk for particular forms of the disease.
• Eye pressure and eye anatomy. Higher baseline IOP, a thin central cornea, marked nearsightedness, and a past eye injury all weigh in.
• Medical history. Diabetes and long-term steroid use are among the systemic factors that raise risk.

If one or more of these fits you, regular eye exams stop being a maintenance chore. They are the whole defense.

How glaucoma is caught and tracked

Because there is no symptom to react to, glaucoma has to be found on purpose. A glaucoma evaluation is not one test but a small battery, each measuring a different piece of the picture, repeated over time so that change shows up early. At Tuli Eye Care Center, that workup usually includes:

• Tonometry measures the pressure inside the eye. A single number is a snapshot, not a verdict, which is why it is read alongside everything below.
• Optic nerve exam and imaging. Dr. Tuli examines the optic nerve directly, and OCT (optical coherence tomography) scans the nerve fiber layer in cross-section, sensitive enough to flag thinning before you would ever notice a gap in your sight.
• Visual field testing maps your peripheral vision point by point, surfacing the early blind spots glaucoma carves out long before they reach the center.
• Gonioscopy uses a mirrored lens to inspect the drainage angle itself and confirm whether it is open or narrow. That distinction separates the types of glaucoma and steers treatment.
• Pachymetry measures corneal thickness, since a thin or thick cornea skews pressure readings and is itself a risk factor worth knowing.

No single result settles the question. Glaucoma is read in the pattern across all of them, followed across visits. That is the real reason follow-up matters here. A one-time normal exam describes today; the comparison between this year and last is what catches a nerve quietly slipping.

Treating glaucoma medically: the role of eye drops

For most patients, glaucoma management opens with medicated eye drops, and for many it stays there for years. The strategy is simple even when the disease is not: lower the pressure inside the eye, ease the load on the optic nerve, and slow or halt further loss. Lowering IOP is the one intervention proven across decades to protect sight in glaucoma.

The drops do this one of two ways: by helping the eye drain fluid more freely, or by telling the eye to make less of it. The main families include:

• Prostaglandin analogs. Often the first choice, these improve the eye's outflow of fluid and are usually dosed once a day.
• Beta-blockers. These cut how much aqueous fluid the eye produces.
• Alpha agonists. These work on both sides of the equation, trimming production and improving outflow.
• Carbonic anhydrase inhibitors. Available as drops or pills, these lower fluid production.
• Rho kinase inhibitors. A newer class that increases drainage through the trabecular meshwork itself.

Which drop, or which combination, is not a guess. The choice is fitted to your target pressure, your other conditions and medications, and how your eyes respond, then adjusted at follow-up based on what the pressure and the nerve are actually doing. Dr. Tuli will walk you through technique, too. A drop that never reaches the eye does nothing, and small habits (closing the eye gently afterward, pressing lightly at the inner corner) improve how much medication does its job and how little reaches the rest of you.

One expectation is worth setting honestly, because it is where treatment most often goes wrong. Glaucoma drops are not a cure, and they are not a course you finish. They are a daily, indefinite commitment, and they work only while you take them. Because the disease causes no symptoms, it is easy to feel fine, decide the drops are unnecessary, and quietly stop. Pressure climbs again with no warning, and the nerve loss resumes in silence. Consistency is not a footnote to glaucoma care. It is the treatment.

When drops alone cannot reach a safe pressure, or when a patient cannot tolerate or reliably use them, the next steps are laser and surgical options, laid out in full on our glaucoma surgery page.

The one thing to hold onto: protection, not repair

If a single idea earns a place in your memory, make it this one. The vision glaucoma has already taken cannot be brought back. Optic nerve fibers, once lost, do not regenerate, and no drop, laser, or surgery restores the sight they carried. Every part of glaucoma care — the screening, the imaging, the daily drops, the repeat visits — exists to protect the vision you have right now from being the next to go.

Seen that way, the silence of glaucoma stops being only a threat and becomes the reason for the whole approach. The disease offers no symptom to act on, so the action has to come first. Found early and managed steadily, glaucoma is, for the large majority of patients, a condition kept in check for life rather than one that ends in blindness. The cost of waiting is the only part that is irreversible.